

# Gerard R Dawson

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11459176/gerard-r-dawson-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64  
papers

3,695  
citations

32  
h-index

60  
g-index

67  
ext. papers

3,998  
ext. citations

6.3  
avg, IF

4.52  
L-index

#	Paper	IF	Citations
64	Validation of the P1vital <sup>®</sup> Faces Set for Use as Stimuli in Tests of Facial Emotion Recognition.. <i>Frontiers in Psychiatry</i> , <b>2022</b> , 13, 663763	5	0
63	Relationships between social withdrawal and facial emotion recognition in neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2022</b> , 113, 110463	5.5	0
62	Cross-disorder and disorder-specific deficits in social functioning among schizophrenia and alzheimer's disease patients.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263769	3.7	0
61	From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. <i>Cell</i> , <b>2021</b> , 184, 5886-5901.e22	56.2	8
60	Accuracy in recognising happy facial expressions is associated with antidepressant response to a NOP receptor antagonist but not placebo treatment. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 1473-1478	4.6	1
59	The clinical effectiveness of using a predictive algorithm to guide antidepressant treatment in primary care (PReDicT): an open-label, randomised controlled trial. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 1307-1314	8.7	11
58	Social dysfunction is transdiagnostically associated with default mode network dysconnectivity in schizophrenia and Alzheimer's disease. <i>World Journal of Biological Psychiatry</i> , <b>2021</b> , 1-14	3.8	2
57	Effect of disease related biases on the subjective assessment of social functioning in Alzheimer's disease and schizophrenia patients. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 145, 302-302	5.2	2
56	Overview of the clinical implementation of a study exploring social withdrawal in patients with schizophrenia and Alzheimer's disease. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2019</b> , 97, 87-93	9	15
55	Predicting treatment response to antidepressant medication using early changes in emotional processing. <i>European Neuropsychopharmacology</i> , <b>2019</b> , 29, 66-75	1.2	24
54	Evidence That Sedative Effects of Benzodiazepines Involve Unexpected GABA Receptor Subtypes: Quantitative Observation Studies in Rhesus Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2018</b> , 366, 145-157	4.7	13
53	The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2017</b> , 18, 558	2.8	20
52	A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. <i>Neuropsychopharmacology</i> , <b>2016</b> , 41, 1803-12	8.7	64
51	Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition. <i>Current Topics in Behavioral Neurosciences</i> , <b>2016</b> , 28, 475-97	3.4	2
50	Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. <i>Psychopharmacology</i> , <b>2013</b> , 227, 331-45	4.7	30
49	Reinforcing effects of compounds lacking intrinsic efficacy at $\alpha$ subunit-containing GABAA receptor subtypes in midazolam- but not cocaine-experienced rhesus monkeys. <i>Neuropsychopharmacology</i> , <b>2013</b> , 38, 1006-14	8.7	16
48	Evaluation of the effects of venlafaxine and pregabalin on the carbon dioxide inhalation models of Generalised Anxiety Disorder and panic. <i>Journal of Psychopharmacology</i> , <b>2013</b> , 27, 135-45	4.6	10

47	A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center double-blind placebo-controlled study. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 469-81	1.2	32
46	Validation of experimental medicine methods in psychiatry: the P1vital approach and experience. <i>Biochemical Pharmacology</i> , <b>2011</b> , 81, 1435-41	6	11
45	Contribution of GABA(A) receptors containing $\beta$ subunits to the therapeutic-related and side effects of benzodiazepine-type drugs in monkeys. <i>Psychopharmacology</i> , <b>2011</b> , 215, 311-9	4.7	22
44	Scopolamine disrupts hippocampal activity during allocentric spatial memory in humans: an fMRI study using a virtual reality analogue of the Morris Water Maze. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1256-65	4.6	39
43	Preliminary evidence of anxiolytic effects of the CRF(1) receptor antagonist R317573 in the 7.5% CO(2) proof-of-concept experimental model of human anxiety. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1199-206	4.6	47
42	Validating the inhalation of 7.5% CO(2) in healthy volunteers as a human experimental medicine: a model of generalized anxiety disorder (GAD). <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1192-8	4.6	30
41	Agomelatine facilitates positive versus negative affective processing in healthy volunteer models. <i>Journal of Psychopharmacology</i> , <b>2011</b> , 25, 1159-67	4.6	50
40	Reducing abuse liability of GABAA/benzodiazepine ligands via selective partial agonist efficacy at alpha1 and alpha2/3 subtypes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2010</b> , 332, 4-16	4.7	58
39	Discriminative stimulus effects of L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine) on the role of GABA(A) receptor subtypes. <i>Neuropharmacology</i> , <b>2010</b> , 58, 357-64	4.7	11
38	In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2009</b> , 331, 470-84	4.7	55
37	The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. <i>British Journal of Pharmacology</i> , <b>2009</b> , 157, 796-803	8.6	10
36	Differential contribution of GABA(A) receptor subtypes to the anticonvulsant efficacy of benzodiazepine site ligands. <i>Journal of Psychopharmacology</i> , <b>2007</b> , 21, 384-91	4.6	42
35	Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist. <i>Neuropharmacology</i> , <b>2007</b> , 53, 810-20	5.5	97
34	The proconvulsant effects of the GABAA alpha5 subtype-selective compound RY-080 may not be alpha5-mediated. <i>European Journal of Pharmacology</i> , <b>2006</b> , 548, 77-82	5.3	9
33	Rat pharmacokinetics and pharmacodynamics of a sustained release formulation of the GABAA alpha5-selective compound L-655,708. <i>Drug Metabolism and Disposition</i> , <b>2006</b> , 34, 887-93	4	21
32	TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine] is an agonist selective for alpha2- and alpha3-containing GABAA receptors, is a non-sedating anxiolytic in rodents and primates. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2006</b> , 316, 410-22	4.7	162
31	The in vivo properties of pargolone in rat are most likely mediated by 5S-hydroxy pargolone. <i>Neuropharmacology</i> , <b>2006</b> , 50, 677-89	5.5	16
30	L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. <i>Neuropharmacology</i> , <b>2006</b> , 51, 1023-9	5.5	143

29	7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine: a functionally selective gamma-aminobutyric acid(A) (GABA(A)) alpha2/alpha3-subtype selective agonist that exhibits potent anxiolytic activity but is not sedating in animal models. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 7089-92	8.3	46
28	Development of subtype selective GABAA modulators. <i>CNS Spectrums</i> , <b>2005</b> , 10, 21-7	1.8	39
27	Effects of reinforcement schedule on facilitation of operant extinction by chlordiazepoxide. <i>Journal of the Experimental Analysis of Behavior</i> , <b>2005</b> , 84, 327-38	2.1	11
26	Anxiogenic properties of an inverse agonist selective for alpha3 subunit-containing GABA A receptors. <i>British Journal of Pharmacology</i> , <b>2005</b> , 144, 357-66	8.6	107
25	Role of GABAA alpha5-containing receptors in ethanol reward: the effects of targeted gene deletion, and a selective inverse agonist. <i>European Journal of Pharmacology</i> , <b>2005</b> , 526, 240-50	5.3	33
24	Evidence for a significant role of alpha 3-containing GABAA receptors in mediating the anxiolytic effects of benzodiazepines. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 10682-8	6.6	199
23	Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 915-20	11.5	158
22	Effects of drugs that potentiate GABA on extinction of positively-reinforced operant behaviour. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2004</b> , 28, 229-38	9	24
21	3-phenyl-6-(2-pyridyl)methoxy-1,2,4-triazolo[3,4-a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding selectivity over alpha 1. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 1807-22	8.3	126
20	Synthesis and biological evaluation of 3-heterocycl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 3642-57	8.3	61
19	Selective, orally active gamma-aminobutyric acidA alpha5 receptor inverse agonists as cognition enhancers. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 2176-9	8.3	92
18	An orally bioavailable, functionally selective inverse agonist at the benzodiazepine site of GABAA alpha5 receptors with cognition enhancing properties. <i>Journal of Medicinal Chemistry</i> , <b>2004</b> , 47, 5829-32	8.3	98
17	Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour. <i>Neuropharmacology</i> , <b>2004</b> , 46, 171-8	5.5	30
16	The GABA-A beta3 subunit mediates anaesthesia induced by etomidate. <i>NeuroReport</i> , <b>2004</b> , 15, 1653-6	1.7	16
15	Genetic mapping of variation in spatial learning in the mouse. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 2426-33	6.6	24
14	Sedation and anesthesia mediated by distinct GABA(A) receptor isoforms. <i>Journal of Neuroscience</i> , <b>2003</b> , 23, 8608-17	6.6	251
13	Fearfulness and sex in F2 Roman rats: males display more fear though both sexes share the same fearfulness traits. <i>Physiology and Behavior</i> , <b>2003</b> , 78, 723-32	3.5	77
12	Identification of a novel, selective GABA(A) alpha5 receptor inverse agonist which enhances cognition. <i>Journal of Medicinal Chemistry</i> , <b>2003</b> , 46, 2227-40	8.3	131

11	3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 1887-900	8.3	111
10	A quantitative trait locus influencing anxiety in the laboratory rat. <i>Genome Research</i> , <b>2002</b> , 12, 618-26	9.7	64
9	6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of GABA-A alpha5 receptor inverse agonists. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 1176-9	8.3	26
8	Learned fear, emotional reactivity and fear of heights: a factor analytic map from a large F(2) intercross of Roman rat strains. <i>Brain Research Bulletin</i> , <b>2002</b> , 57, 17-26	3.9	59
7	Anxiolytic-like action of diazepam: which GABA(A) receptor subtype is involved?. <i>Trends in Pharmacological Sciences</i> , <b>2001</b> , 22, 402-3	13.2	24
6	Loss of the major GABA(A) receptor subtype in the brain is not lethal in mice. <i>Journal of Neuroscience</i> , <b>2001</b> , 21, 3409-18	6.6	193
5	A strategy to home-in on polygenes influencing susceptibility to anxiety. <i>Human Psychopharmacology</i> , <b>1999</b> , 14, S3-S10	2.3	0
4	Use of the elevated plus maze in the search for novel anxiolytic agents. <i>Trends in Pharmacological Sciences</i> , <b>1995</b> , 16, 33-6	13.2	399
3	One-trial tolerance to the effects of chlordiazepoxide on the elevated plus maze may be due to locomotor habituation, not repeated drug exposure. <i>Psychopharmacology</i> , <b>1994</b> , 113, 570-2	4.7	76
2	The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo. <i>Life Sciences</i> , <b>1993</b> , 52, 489-95	6.8	43
1	The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. <i>Behavioural Brain Research</i> , <b>1993</b> , 57, 143-53	3.4	74